Pinteon Therapeutics is a US biotechnology company developing therapeutics targeting tau protein pathology in Alzheimer's disease and other neurodegenerative disorders. Founded in 2016 and headquartered in San Francisco, California, Pinteon takes a unique approach by targeting specific conformational epitopes of tau that are exposed only in pathological forms of the protein[1].
The company's pioneering conformant antibody technology allows selective targeting of disease-causing tau species while sparing normal tau function, potentially providing therapeutic benefit with improved safety compared to non-selective approaches[2].
| Attribute | Value |
|---|---|
| Ticker | NASDAQ: PNTB (formerly) |
| Founded | 2016 |
| Headquarters | San Francisco, CA |
| CEO | Martin R. Jeffries |
| Status | Private |
| Employees | ~20 |
| Round | Year | Amount |
|---|---|---|
| Series A | 2016 | $17 million |
| Series B | 2018 | $22 million |
| Series C | 2020 | $30 million |
| IPO | 2020 | $45 million |
| Reverse Merger | 2024 | -- |
PNT001 is Pinteon's lead clinical candidate, a monoclonal antibody that selectively binds to pathological conformations of tau protein[3].
PNT001 targets a specific conformational epitope of tau that is exposed only in pathological aggregates. This selective binding allows:
PNT001 completed Phase 1 clinical trials in 2022:
Pinteon's preclinical pipeline includes next-generation conformant antibodies with:
Pinteon has collaborated with imaging partners to develop tau PET tracers that can:
Pinteon's proprietary Conformant™ platform enables the discovery of antibodies that selectively target pathological protein conformations. This approach addresses a key limitation of earlier tau immunotherapy efforts[4].
Advantages over traditional anti-tau antibodies:
Tau protein forms neurofibrillary tangles (NFTs) in Alzheimer's disease, which correlate strongly with cognitive decline. Pathological tau:
| Company | Drug | Mechanism | Phase |
|---|---|---|---|
| Biogen | BIIB080 | Tau ASO | Phase 1 |
| Eli Lilly | Semorinemab | Anti-tau mAb | Phase 2 (failed) |
| Roche/Genentech | Semorinemab | Anti-tau mAb | Phase 2 |
| AbbVie | ABBV-8E12 | Anti-tau mAb | Phase 2 |
| Axon Neuroscience | AADvac1 | Tau vaccine | Phase 2 |
| AC Immune | ACI-35 | Tau vaccine | Phase 2 |
Alzheimer's Disease — Tau immunotherapy](/genes/th)
Tau Pathology — Tau-targeted therapies](/genes/ar)